|
WO2021068866A1
|
|
Heterocyclic compounds as sting modulators
|
|
WO2021058018A1
|
|
Inhibitors of kras g12c
|
|
WO2021058017A1
|
|
Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use
|
|
WO2021047623A1
|
|
Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
|
|
WO2021032148A1
|
|
Aminopyrazine compounds as hpk1 inhibitor and the use thereof
|
|
WO2021023105A1
|
|
Imidazo[2,1-f][1,2,4]triazin-4-amine derivative used as tlr8 agonist
|
|
WO2021018018A1
|
|
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
|
|
WO2021013234A1
|
|
Cyclic dinucleotides as sting agonists
|
|
WO2021013083A1
|
|
Tricyclic compounds as hpk1 inhibitor and the use thereof
|
|
WO2021000925A1
|
|
PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF
|
|
WO2020239097A1
|
|
Parp inhibitor pellet preparation and preparation process therefor
|
|
WO2020233676A1
|
|
Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenases
|
|
WO2020160711A1
|
|
Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
|
|
TW202043225A
|
|
Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefor
|
|
WO2020103896A1
|
|
Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
|
|
WO2020048409A1
|
|
1,5-NAPHTHYRIDIN-4(1H)-ONE DERIVATIVES AS PI3Kbeta INHIBITORS
|
|
TW202016116A
|
|
Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
|
|
CN112243439A
|
|
Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof
|
|
CN112292133A
|
|
PARP inhibitor maintenance therapy in the treatment of gastric cancer
|
|
EP3797123A1
|
|
Anti-ox40 antibodies and methods of use
|
